First Venture

Andreas Lindenhierta leads the firm as CEO, a role he assumed in 2025. He works alongside Chairman Christina Källenfors and the firm's network of specialist advisors to evaluate opportunities. Founder Rune Nordlander and former Chairman Peter Werme remain on the board, providing continuity.

The firm explicitly targets companies in the negative-cash-flow phase between initial R&D and market traction—a stage where most startups fail due to lack of funding. First Venture views this as an opportunity for lower competition and higher potential value growth, deploying patient minority capital and hands-on governance to guide companies toward a public listing.

In unlisted companies, First Venture takes an active board role and coaches the entrepreneur team directly, with the goal of achieving a public listing within approximately three years. For already-listed holdings, the firm influences governance through nomination committees rather than board seats, while maintaining ongoing contact with management.

The firm invests solely within three megatrends: technology, health, and sustainability. Its active holdings illustrate this focus—Sprint Bioscience represents the health trend in preclinical oncology, while Lyckegård targets sustainability through agricultural technology and advisory services.

First Venture is a publicly listed Swedish investment company, which gives it a permanent capital base not available to typical closed-end venture funds. It takes minority positions and has a strategic shareholder relationship with Peter Gyllenhammar AB, a major co-investor.

First Venture makes direct minority equity investments into individual operating companies. There is no public record of the firm making fund commitments or acting as a fund-of-funds; its model relies on direct, active involvement with portfolio company management teams.

Each potential investment is analyzed individually against international ESG guidelines and UN Global Compact principles. The firm states that companies it views as unsustainable over the long term cannot meet its capital-return requirements, and it applies a proprietary analysis model to screen for compliance.